Using radiofrequency ablation to treat liver cancer by targeting sympathetic nerves
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
This study is testing a new treatment for advanced liver cancer that combines a special heat procedure with surgery to target nerves, to see if it helps patients who haven't responded to other therapies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 25 Years to 75 Years |
| Sex | All |
| Sponsor | Zhongda Hospital Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06694636 on ClinicalTrials.gov |
What this trial studies
This clinical trial involves patients with hepatocellular carcinoma (HCC) who are treated with endovascular radiofrequency ablation combined with desympathetic nerve surgery. The approach aims to assess the safety and efficacy of this treatment method in patients with advanced, unresectable HCC who have progressed after second-line therapy. Following the procedure, patients will undergo regular follow-up evaluations, including blood tests and imaging studies, to monitor their condition and treatment response.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with clinically or pathologically confirmed hepatocellular carcinoma that is locally progressed or metastatic and unresectable.
Not a fit: Patients who are not suitable for ablation surgery or have other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced liver cancer who have limited treatment choices.
How similar studies have performed: While this approach is innovative, similar studies using radiofrequency ablation for liver cancer have shown promising results, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically or pathologically confirmed hepatocellular carcinoma (HCC) * Locally progressed or distant metastatic unresectable advanced HCC * Progressed after second-line therapy * Agree to participate in the study and sign the informed consent form Exclusion Criteria: * Not suitable for ablation surgery * Pregnant, lactating and planning to become pregnant * Orthostatic hypotension * Mixed liver cancer * Intestinal obstruction * Obvious bleeding tendencies and hematologic diseases * Acute or severe systemic infection; * Stroke or transient ischemic attack (TIA) within two weeks; * Acute coronary syndrome within two weeks; * Evaluated to be not suitable for this trial by investigators
Where this trial is running
Nanjing, Jiangsu
- Zhongda Hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Gao-Jun Gao-Jun — Zhongda Hospital
- Study coordinator: Hai-Dong Zhu
- Email: zhuhaidong9509@163.com
- Phone: +86-25-83272121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.